Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ASML Hld

SAP SE

TotalEnergies SE

The world's largest hedge fund has almost doubled the size of its short bet against European companies in the past week. Bridgewater Associates, the US$150bn hedge fund colossus founded by Ray Dalio, now has at least US$10.5bn of short positions on a total of 28 companies, according to research from Bloomberg, up from US$5.7bn over 18 shares a week ago.

World's largest hedge fund doubles its short bet on European shares

British American Tobacco

Diageo

Novartis

Imperial Brands PLC

Well, that didn't last long. As we suspected, each and every market rally until the Federal Reserve completes the interest rate hike cycle likely will be met with selling as investors try to go to cash and get away from the market's downward spiral.

Why These 5 European Dividend Aristocrats (Some With Huge Yields) Are Incredible Q3 Buys

NEW YORK (Reuters) -Bridgewater Associates has placed at least $6.7 billion in bets against European stocks, according to data group Breakout Point, in a sign that the hedge fund firm may be pessimistic about companies on the continent.

Bridgewater bets $6.7 billion against European stocks

Data from clinical studies show that Sanofi (SNY) and Glaxo's (GSK) next-generation COVID-19 booster candidate elicits a stronger immune response in adults who received an mRNA vaccine as a primary regimen.

Sanofi (SNY), GSK COVID Booster Jab Effective Against Omicron

GlaxoSmithKline

The shot provoked a stronger immune response against omicron than a booster dose of Pfizer's vaccine, Sanofi said.

Sanofi, GSK Covid Booster Triggers ‘Strong Immune Response' Against Multiple Variants Including Omicron

Sanofi - GSK next-gen eration COVID-19 booster delivers strong immune response against variants of concern, including Omicron

Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron

Ergomed PLC (AIM:ERGO, ETR:2EM) said Anne Whitaker will join its board as an independent non-executive director after the pharmaceutical industry service provider's AGM on Friday. She has worked across the pharmaceutical, biotech and speciality pharma sectors for 30 years including in senior executives roles at Sanofi, GlaxoSmithKline and Synta Pharmaceuticals.

Ergomed appoints former GSK and Sanofi executive to board

AstraZeneca

Vaxart

It depends on which subsector you're talking about.

What Could a Recession Mean for Healthcare Stocks?

Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.

Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants

Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth

FDA a pproves Dupixent ® (dupilumab) as f irst b iologic m edicine for c hildren a ged 6 m onths to 5 y ears with m oderate-to-severe a topic d ermatitis

Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

2,500 Sanofi Massachusetts-based employees come together in a shared space to improve collaboration while growing our science-centered, patient-focused culture Single integrated campus supports Play to Win strategy to focus on growth, lead with innovation, accelerate efficiencies, and reinvent the way we work CAMBRIDGE, Mass. , June 7, 2022 /PRNewswire/ -- Sanofi announces the opening of the company's new campus at Cambridge Crossing in Cambridge, Massachusetts.

Sanofi unveils new 900,000-square-foot campus at Cambridge Crossing

Sanofi launches 2022 global E mployee S tock P urchase P lan for 86.000 people

Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people

The FDA bestows a Breakthrough Therapy designation to Sanofi's (SNY) efanesoctocog alfa for the treatment of people with hemophilia A.

Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug

Regeneron Pharmaceuticals

Regeneron will gain exclusive worldwide development, commercialization, and manufacturing rights to the drug Libtayo.

Regeneron Will Buy Cancer Drug Rights From Sanofi for Up to $1.1 Billion

Regeneron Pharmaceuticals Inc. REGN, -0.88% announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s SNY, -0.08% stake in the Regeneron-Sanofi collaboration on cancer treatment Libtayo.

Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaboration

Sanofi grant s Regeneron worldwide exclusive license rights to Libtayo ® ( cemiplimab )

Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)

Sanofi SNY, -3.45% SAN, +1.17% said Wednesday that the Food and Drug Administration granted a Breakthrough Therapy designation to the hemophilia A treatment it's developing with Swedish Orphan Biovitrum AB SOBI, +5.00% . The company said it plans to ask the FDA to approve efanesoctocog alfa this summer.

FDA gives Sanofi's experimental hemophilia A drug a Breakthrough Therapy designation

The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for review submitted by Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) for the lead drug candidate Dupixent (dupilumab) for the treatment of patients with prurigo.

FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease

The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.

Sanofi's (SNY) Dupixent Prurigo Nodularis NDA Gets Priority Tag

The setback could raise fears about the future of the French company's consumer division, which is also seeing delays in an OTC version of Tamiflu.

Sanofi Ordered to Delay Trial for OTC Cialis. The Stock Falls.

STERIS

Market downturns don't affect stocks equally.

3 Unstoppable Stocks That Are Higher Than Before the Market Correction

Sanofi's strong reliance on a single product Dupixent poses risks as competition in atopic dermatitis segment increases. It struggled to show any superiority in COVID-19 vaccine development and is still catching up with mRNA technology.

Sanofi: Reliance On One Drug Strategy May Bite

Alkermes

Sesen Bio Inc.

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

News for Sanofi Stock (SNY)